A Deep Dive into Emerging Therapies in the Management of Atopic Dermatitis: Managed Care Considerations on Recent Clinical Data in an Evolving Treatment Landscape

A continuing medical education activity sponsored by NAMCP and AAMCN.

Confronting the Clinical and Economic Burden of Atopic Dermatitis:
Managed Care Considerations in an Evolving Treatment Paradigm

This is Part 1 of the series focusing on managed care considerations in an evolving treatment landscape

This activity is an archive from the webinar held May 11, 2020

This activity is valid from June 1, 2020 to June 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Pfizer Inc.

Description:
Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Fortunately for patients with this disease, several new treatments have recently become available, and more are on the horizon, including JAK inhibitors, that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.

Upon completion of this activity, participants will be able to:

  • Explore the unmet clinical needs in atopic dermatitis (AD) and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity

  • Review recent pathophysiological findings in AD that have informed the study of new therapeutic targets, including JAK inhibitors

  • Examine new evidence pertaining to the safety and efficacy of new and emerging therapies in the management of AD

  • Analyze the role of emerging JAK inhibitors in the management of AD for patients of all ages


     

Faculty: Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine

Disclosure:

Dr. Sidbury has served on an advisory board for Pfizer and has received grants or research from Galderma and Regeneron. He serves as a consultant for Micreos. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Pfizer Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue